Therapeutics | search
Click here to view Therapeutics news from 60+ newspapers.
Bookmark or Share- PTGX Stock Earnings: Protagonist Therapeutics Beats EPS ... - InvestorPlaceProtagonist Therapeutics reported earnings per share of $3.26. This was above the analyst estimate for EPS of $2.51. The company reported revenue of $254.95 million.
- Esperion Therapeutics, Inc. 2024 Q1 - Results - Seeking AlphaThe following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2024 Q1 earnings call. View as PDF. Click to Enlarge. 1 24. This article was written by.
- Esperion Therapeutics: Q1 Earnings Snapshot - The Washington PostANN ARBOR, Mich. — ANN ARBOR, Mich. — Esperion Therapeutics Inc. (ESPR) on Tuesday reported first-quarter net income of $61 million. On a per-share basis, the Ann Arbor, Michigan-based company ...
- COVID-19 Treatments and Therapeutics | HHS.govAfter a public health emergency was declared for the COVID-19 pandemic, it was determined that the Food and Drug Administration (FDA) could authorize the emergency use of tests, treatments, and vaccines to reduce suffering, loss of life and restore the health and security of our country. The FDA issued emergency use authorizations (EUAs) to ...
- RNA-based therapeutics: an overview and prospectus - PMCRNA-based therapeutics were firstly adopted for diseases with clear rationales, such as oncology, neurological disorders and infectious diseases. Recent advancements in RNA technologies have led to the approval of eight ASOs, three siRNAs, and two mRNA vaccines for COVID-19 under the Emergency Use Authorization scheme (Table (Table2). 2 ).
More
